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Abstract: The purpose of this review is to compile preclinical and clinical results on 
phthalocyanines (Pcs) as photosensitizers (PS) for Photodynamic Therapy (PDT) and 
contrast agents for fluorescence imaging. Indeed, Pcs are excellent candidates in these fields 
due to their strong absorbance in the NIR region and high chemical and photo-stability.  
In particular, this is mostly relevant for their in vivo activation in deeper tissular regions. 
However, most Pcs present two major limitations, i.e., a strong tendency to aggregate and a 
low water-solubility. In order to overcome these issues, both chemical tuning and 
pharmaceutical formulation combined with tumor targeting strategies were applied. These 
aspects will be developed in this review for the most extensively studied Pcs during the last 
25 years, i.e., aluminium-, zinc- and silicon-based Pcs. 
Keywords: biomedical optics; fluorescence diagnosis; phthalocyanines; NIR dyes; 
photodynamic therapy 
 
1. Introduction 
The first syntheses of metal-free and copper phthalocyanines were reported in 1907 by Braun and 
Tcherniac at the South Metropolitan Gas Company (United Kingdom) and in 1927 by Diesbach and 
von der Weid at the University of Fribourg (Switzerland). A few years later, Professor Linstead in 
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collaboration with Imperial Chemical Industries (ICI) was the first to characterize the chemical 
structure of the phthalocyanine molecule, using for the first time the term “phthalocyanine” [1-3]. 
Nowadays, phthalocyanines are widely used in the dying industry. Nearly a quarter of all pigments 
of organic origin are related to this class of compounds. Furthermore, they are used for the fabrication 
of high-speed and high resolution optical media [4], as light harvesters in photovoltaic applications [5], 
and as experimental catalysts in redox reactions [6]. These dyes absorb strongly in the red and near 
infrared (NIR) part of the visible spectrum providing them with their characteristic blue or greenish 
color. Pcs that absorb in the NIR are especially interesting for photomedical applications such as 
fluorescence imaging, Photochemical Internalisation (PCI), and Photodynamic Therapy (PDT) [7-12]. 
Just recently Photochemical Internalisation (PCI), a novel drug delivery process, has shed light on 
the importance of phthalocyanines and their applications in oncology [13-15]. The PCI technology  
is based on the concomitant administration of a therapeutic agent and a photosensitizer.  
When internalized by endocytosis and consequently colocalized in the endosomes and/or lysosomes, 
light activation of the PS will subsequently lead to vesicle disruption and release of the therapeutic 
agent. Indeed, PCI technology enables the release of endocytosed drugs prior to lysosomal 
degradation, thus, increasing their therapeutic efficacy within the target cells. Among the 
photosensitizers used in PCI, the amphiphilic disulfonated aluminium phthalocyanine AlPcS2adj 
displays all the required features and characteristics such as specific insertion of the hydrophobic part 
of the PS into the endocytotic membrane. Due to its amphiphilic character, AlPcS2adj “intrudes into the 
plasma cell membrane, but is unable to penetrate through the plasma membrane and will enter the cells 
via adsorptive endocytosis” [16]. The concomitant administration of a drug such as gelonin or 
bleomycin [14,17,18] will, after internalization lead to vesicle disruption and intracellular release of 
the drug upon light activation [14,19,20]. 
As mentioned previously, phthalocyanines strongly absorb in the NIR, and have been proposed for 
PDT of cancer as early as 1985 [21,22]. Under some circumstances PDT treatment presents several 
advantages over conventional cancer therapies such as chemo, radiation and surgical treatments.  
It enables selective destruction of malignant tissues due to specific interaction of three individually 
non-toxic components i.e., a photosensitizer (PS), light and oxygen. PS selective accumulation in 
tumor combined with its controlled light activation enables selective destruction of tumors, sparing 
neighboring healthy tissue. 
Although today the selectivity of PS is not fully understood, it is thought to be a multifactorial 
process including physico-chemical properties and binding to plasma proteins as well as the particular 
characteristics of tumors such as leaky vasculature, low lymphatic drainage, expression of specific 
enzymes and receptors and pH variation. Depending on its cellular and intracellular 
localization/relocalization, PS exhibits direct and indirect cell killing, vascular occlusion, release of 
cytokines and the response of the immune system [23,24]. 
Photofrin® (Table 1) was the first photosensitizer approved for clinical use in 1993 for the treatment 
of bladder cancer. Since then it gained marketing for the prophylactic treatment of several cancers such 
as the treatment of early-stage oesophagal, gastric, cervical and lung cancers [24,25]. However, this first 
generation photosensitizer has several limitations with respect to its clinical use since it [23,25-28]: 
Molecules 2012, 17              
 
 
100
 Is composed of a undefined mixture of hematoporphyrin derivatives (HpD); 
 Induces a long-lasting skin photosensitization (2 to 3 months post injection);  
 Has a low extinction coefficient at wavelengths for optimal tissue penetration;  
 Displays a limited selectivity for the target tissue.  
Therefore, considerable efforts have been undertaken to prepare 2nd generation PS with more 
suitable features [29-31] such as:  
 Single and chemically pure compound; 
 Stability and good solubility in pharmaceutically acceptable formulations and in biological 
media; 
 Low tendency to aggregate; 
 High singlet oxygen quantum yield; 
 Photostability; 
 Fluorescence; 
 Low phototoxicity towards healthy tissue;  
 No dark toxicity; 
 Fast clearance from the healthy parts of the body and specific retention in diseased tissues; 
 Strong absorbance in NIR region and minimal absorbance between 400 and 600 nm. 
In order to avoid skin photosensitization, the PS has to present the lowest absorbance in the spectral 
range where daylight intensity is the highest, i.e., between 400 and 600 nm. Moreover, strong 
absorbance in the NIR region between 600 and 900 nm favors the optimal penetration of light into 
tissues, thus resulting in more efficient PDT effects when treating deeper lying lesions. However, 
absorption by water molecules increases for wavelengths above 800 nm and at higher wavelength 
energy transfer to molecular oxygen is suboptimal. Hence, the window for optimal light penetration 
ranges from 600 to 800 nm. These considerations are based on the assumption that healthy and 
diseased tissues have the same absorbance of light, which in reality is not the case. Finally, 94 kJ/mol 
appears to be the minimal energy required by a photon to induce singlet oxygen 1O2 formation. This 
energy corresponds to a wavelength of approximately 1,270 nm [32-39]. 
In Table 1 some 1st and 2nd generation PS investigated in clinical trials and their potential 
therapeutic application in oncology are listed (see also Figure 1 for their chemical structures). 
Table 1. Examples for PS used in clinical and preclinical trials in oncology [24,25,40-52]. 
Photosensitizers  Trade Name Absorption Wavelength Potential Indications 
HpD,  
Porfimer sodium 
Photofrin, 
Photogem, 
Photosan, 
Hemporfin 
630 nm  
Cervical, brain, oesophageal, breast, head and 
neck, lung, bladder, superficial gastric 
cancers, Bowen's disease, cutaneous Kaposi's 
sarcoma 
m-THPC,  
Temoporfin 
Foscan 652 nm  
Oesophageal, prostate and pancreatic cancer, 
advanced head and neck tumors 
Verteporfin Visudyne 689 nm Basal and squamous cell carcinomas 
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Table 1. Cont. 
Photosensitizers  Trade Name Absorption Wavelength Potential Indications 
HPPH,  
2-(1-hexyloxyethyl)-2-devinyl 
pyropheophorbide-alpha 
Photochlor 665 nm 
Basal cell carcinoma, Oesophageal 
cancers, Head and Neck tumors  
Palladium-bacteria-
pheophorbide 
Tookad 763 nm Prostate cancer 
5-ALA, 
5-aminolevulinic acid 
Levulan 
630 nm  
Skin tumors, head and neck, 
gynaecological tumors and basal cell 
carcinomas 
375–400 nm 
Brain, head and neck and bladder 
cancer photodetection 
5-ALA-methylester Metvix 635 nm Basal cell carcinoma 
5-ALA benzylester Benzvix 635 nm Gastrointestinal tumors 
5-ALA hexylester Hexvix 375–400 nm Photodectection of bladder cancer 
Lutetium (III)-texaphyrin or 
Motexafin-lutetium 
Lutex, Lutrin, 
Antrin, Optrin
732 nm 
Prostate, cervical, breast, brain cancer, 
melanoma 
SnET2, Tin (IV) ethyl 
etiopurpurin 
Purlytin, 
Photrex 
659 nm 
Kaposi's sarcoma, cutaneous metastatic 
adenocarcinomas, prostate, brain, lung 
cancers, basal cell carcinomas 
NPe6, mono-L-aspartyl 
chlorin e6, talaporfin sodium 
Talaporfin, 
Laserphyrin 
664 nm 
Solid tumors, lung cancer, cutaneous 
malignancies 
BOPP, boronated 
protoporphyrin 
BOPP 630 nm  Malignant gliomas 
Zinc phthalocyanine CGP55847 670 nm 
Squamous cell carcinoma of upper 
aerodigestive tract 
Silicon phthalocyanine Pc 4  675 nm 
Cutaneous and subcutaneous lesions 
from diverse solid tumor origins 
Mixture of sulfonated 
aluminium phthalocyanine 
derivatives 
Photosens  675 nm 
Skin, breast, lung, oropharingeal, 
breast, larynx, head and neck cancers, 
Sarcoma M1, epibulbal and choroidal 
tumors, eyes and eyelids tumors, 
cervical cancer 
ATMPn, Acetoxy-tetrakis 
(β-methoxyethyl)-porphycene  NA 600–750 nm Skin cancer 
TH9402, dibromorhodamine 
methyl ester  
NA 515 nm 
Breast, myeloma, non-melanoma skin 
cancer 
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Figure 1. Chemical structures of clinically relevant “non-phthalocyanine” photosensitizers. 
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Another appealing feature of Pcs is the ease of the introduction of peripherial and axial substituents 
that can be used to fine tune absorption and emissions characteristics. Phthalocyanine dyes with 
absorptions bands as high as 1,000 nm with suitable fluorescence quantum yields can be prepared [11]. 
Therefore, Pcs are potentially interesting as fluorescence reporters for in vitro and in vivo imaging that 
can replace commonly used fluorophors such as fluorescein and indocyanine green. Two of such 
compounds, “La Jolla Blue®” and “IRD700DX®” are commercially available as labeling agents for 
proteins, peptides [53-55], antibodies [56-60] and oligonucleotides [61-65]. 
This review intends to compile preclinical and clinical data accrued with Pcs as PS for PDT. 
However, it has to be noted that the presented concepts can be easily translated into the use of similar 
compounds for the fluorescence diagnosis of disease. Thereby, we will mainly focus on the most 
extensively studied Pcs, i.e., Pcs containing Al, Zn, and Si as central metal ion. At first we will briefly 
describe how chemical modulation of Pcs, alters their Structure-Activity Relationship (SAR). Then, 
since most Pcs are barely soluble in pharmaceutically acceptable formulations special emphasis will be 
placed on the impact of pharmaceutical formulation on their therapeutic efficiency. And finally, 
different tumor targeting strategies that have been exploited with Pcs will be discussed. 
2. Phthalocyanines 
Pcs belong to the group of 2nd generation PS which exhibit a high extinction coefficient around  
670 and 750 nm and even up to 1,000 nm. Variation of the axial and peripheral substituents modulates 
the tendency for aggregation, pharmacokinetics, biodistribution, solubility, as well as fine-tuning of 
NIR absorbance [66]. Extinction coefficients higher than 105 M−1cm−1 have been reported [11,66]. 
These compounds are porphyrin-like PS, displaying tetrapyrrolic, aromatic macrocycles with each 
cycle linked to the other by nitrogen atoms. Each pyrrolic ring is extended by a benzene ring resulting 
in the red-shift of their final absorption band [31,67,68]. Figure 2 shows the general chemical structure 
of Pcs and nomenclature as well as typical absorption and emission spectra. 
Figure 2. (a) General chemical structure of metallated phthalocyanines; (b) Typical 
absorption and emission spectra of metallated Pc (e.g., zinc based phthalocyanine in DMSO). 
 
(a) 
Molecules 2012, 17              
 
 
104
Figure 2. Cont. 
 
(b) 
Lowering of the symmetry of the phthalocyanine molecules results in splitting (or broadening) of 
the Q bands. This splitting is due to the lifting of degeneracy of the lowest unoccupied molecular 
orbital (LUMO) to a varying extent. It is also well established that expansion of  conjugation in 
phthalocyanines shifts the Q band to the red. Extension of the conjugation system is accompanied by 
change in colour from blue/green to colors including brown, red or purple. The location of the Q band 
in Pc complexes can be adjusted by attaching suitable substituents onto the peripheral and  
non-peripheral positions of the ring and by the change in the nature, size and number of substituents. 
Addition of electron donating groups such as –NH2, OR and SR at the non-peripheral 
(1,4,8,11,15,18,22,25) or peripheral (2,3,9,10,16,17,23,24) positions of the Pc ring results in red shift 
to the NIR region. Substitution at the non-peripheral position shows more red-shift than at the 
peripheral position [69]. 
Besides their strong absorption in the NIR, Pcs exhibit low absorption at wavelengths between  
400 and 600 nm leading potentially to a lower skin photosensitization when exposed to sunlight [31]. 
Moreover, the presence of a diamagnetic central metal such as Zn2+ and Al3+ in the Pc nucleus seems 
to improve the triplet state life time (τt), as well as its yield (Фt) and singlet oxygen yields (ФΔ) 
compared to paramagnetic metals (e.g., ФΔ ≥ 0.7, Фt > 0.4 and τt = 750 s for AlPcS4 in solution with 
human serum albumin) [30,48,67,70]. However, the metallation is not required for its photodynamic 
activity. Indeed, Feofanov et al. [71] and Karmakova et al. [72] reported efficient antitumor activity of 
a mixture of metal-free sulfonated phthalocyanines with an average number of sulfonated groups of 2.4 
in vitro on human epidermoid carcinoma cells HEp2 and in vivo on mice bearing murine P-388 
lymphoma cells, respectively. 
On the other hand, Pcs with good fluorescence quantum yields up to 0.6 have been reported.  
This, together with their high photostability compared to commonly used labeling agents should have 
placed this group of compounds into the upper part of the list of NIR fluorescence reporters. As an 
example IR700DX® is about 20 times more stable than Cy5.5 at similar irradiation intensities and 
wavelengths. However, despite these photophysical and spectral characteristics the use of Pcs as 
labeling agents for fluorescence imaging or in PDT is still limited. 
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2.1. Aluminium Based Phthalocyanines 
2.1.1. Aluminium Sulfonated Phthalocyanines—SAR 
Sulfonated phthalocyanines bearing a central aluminium ion have been extensively studied in vitro 
as well as in vivo. They display potent photodynamic activity on cell lines including G361 human 
melanoma cells [73], pancreatic carcinoma cells (H2T) [74], and human fibrosacroma cells  
(HT-1080) [75], as well as in vivo on rat (CBH rats) bearing fibrosarcoma (HSN/TC/7) [76].  
These early studies indicated a strong dependence of the photodynamic efficiency on the degree of 
sulfonation, later systematically assessed by Chan et al. [77-79]. 
At this point one has to keep in mind that earlier reports on aluminium sulfonated phthalocyanines 
can be sometimes misleading due to the designation as AlPcS4 or as AlPcS of the commercially 
available product from Ciba-Geigy, which nevertheless consisted of a mixture of mono, di-, tri- and 
tetrasulfonated chloroaluminium phthalocyanines with an average degree of three sulfonated 
substituents. Thus, in this review, we will refer to this mixture as AlPcS, whereas AlPcS4 will be used 
to qualify the pure tetrasulfonated Pc, keeping in mind that even these more defined compounds will 
be mixtures of regio- and stereoisomers. Furthermore, some early works did not disclose the identity of 
the axial ligands which could be chloride (Cl) as well as hydroxy (OH) groups. Since most reported 
studies focus on the effect of sulfonation with respect to PDT, no further distinction according to their 
axial ligand will be made here. Finally, the IC50 values reported in this review cannot be compared 
from a study to another since this value depends among other things on the applied light doses. 
Interestingly, AlPcS4 has shown promising in vivo results in the treatment of malignant gliomas [80,81]. 
Wistar rats inoculated intracranially with C6 glioma cells, responded within 5 days to intravenous 
injection of AlPcS4 in saline solution at a dose of 5 mg/kg and irradiation 6 h post administration at a 
dose of 100 J/cm2. However, upon illumination at a light dose of 200 J/cm2, AlPcS4-mediated PDT 
neurological symptoms (e.g., brain damage and oedema) appeared, while light alone had no effect. 
Higher light doses lead to death in mice bearing intracerebrally implanted VMDk murine glioma cells 
as reported by Sandeman et al., presumably concomitant with hyperthermic effects in the irradiated 
areas [82].  
2.1.2. Influence of the Degree of Sulfonation 
In 1990, Chan et al. reported that in vitro monosulfonated chloroaluminium phthalocyanine 
(AlPcS1) was taken up faster, retained to a higher degree and showed higher phototoxicity in murine 
colorectal carcinoma (Colo-26) cells than higher sulfonated analogues (i.e., di, tri and tetrasulfonated 
chloroaluminum phthalocyanine; referred to as AlPcS2, AlPcS3 and AlPcS4 respectively) [77]. 
Furthermore, comparison of light doses necessary for efficient PDT on WiDr cells cultured in monolayers 
and as spheroids revealed that spheroids were less sensitive to PDT than cells grown in monolayers [78]. 
In contrast to in vitro experiments, an inverse tendency with respect to tumor accumulation and 
phototoxicity was observed when PDT was perfomed with this series of sulfonated Pcs in vivo.  
In BALB/c mice inocculated with Colo-26 tumors AlPcS1 had essentially no effect on tumor regression 
in contrast to the higher sulfonated compounds following the order AlPcS4 > AlPcS3 > AlPcS2 [77]. 
This discrepancy can be assigned to differences in pharmacokinetics and biodistribution of these 
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compounds due to their differences in hydrophilicity [77,83]. As suggested by Chan et al., the fast 
clearance of highly sulfonated Pcs after intravenous administration can be circumvented by 
intraperitoneal application for these compounds [77]. 
Later, Chan et al. showed that AlPcS2 was more potent than AlPcS3 and AlPcS4, despite its lower 
accumulation in tumor xenografts. This suggests different PDT mechanisms of these compounds with 
respect to cell killing, vasculature occlusion, and intracellular localization [78]. Interestingly, the highest 
in vitro efficiency of AlPcS2 over other more hydrophilic aluminium sulfonated Pc was already 
demonstrated in 1988. The same tendency was later confirmed by Peng and Moan [83]. When injected 
intraperitoneally AlPcS2 was the most efficient PS followed by AlPcS4, Photofrin, and AlPcS1. The best 
efficiency was observed with a drug dose of 10 mg/kg and light exposure 2 h post-administration. 
Moreover, the relative position of sulfonate group seems also to influence Pcs photoactivity. Indeed, 
AlPcS2 bearing adjacent sulfonated side-group (AlPcS2adj) rather than opposite side-substitution 
exhibited the best cell penetration and were the most phototoxic compounds amongst the sulfonated 
aluminium phthalocyanine serie, presumably due to their amphiphilic properties [84]. Therefore,  
the phototoxicity of mixed AlSPc in vivo should be related mostly to photoactivity of AlPcS2adj 
isomers [78,83]. In a recently reported study, Mathews et al. compared the phototoxic effect of 
AlPcS2adj to 5-aminolevulinic acid (5-ALA) on healthy brains in mice [85]. Based on PDT-induced and 
higher mortality rates, AlPcS2adj was considered to be a more potent photosensitizer than 5-ALA. 
Moreover, in a comparative study, Gupta et al. [86] reported that liposomal formulation of AlPcS2 
resulted in a higher phototoxic effect as compared to its free form on human glioma cells (BMG-1) 
despite its lower uptake by the cells.  
Despite the higher efficiency of AlPcS2 compared to other sulfonated aluminium phthalocyanines, 
extensive efforts and studies have been realized with the objective of further improving the 
pharmacokinetic properties and selectivity of the commercially available AlPcS4.  
Allen et al. [26], tested sulfonamides with an alkyl chain of 4, 8, 12 and 16 carbons to one of the 
sulfonated groups in AlS4Pc (Figure 3) and compared induced photodynamic effects to AlPcS4 in mice 
bearing EMT-6 tumors. They concluded that at doses of 0.2 μmol/kg, all tested AlPcS4-derivatives 
induced tumor regression and were more effective than AlPcS2adj or AlPcS4. Moreover, with increasing 
alkyl chain length increased photodynamic efficacy was observed. In these experiments, AlPcS4 had no 
effect at doses up to 5 μmol/kg, and 1 μmol/kg of AlPcS2adj was needed to induce 87% of tumor cure.  
Figure 3. A homologous series of AlPc alkylsulfonamides. 
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2.1.3. Photosens® 
Photosens®, a mixture of aluminium chloride phthalocyanines with 1 to 4 sulfonated side-groups 
with an average sulfonated degree of 3, was developed at the General Physics Institute of the Russian 
Academy of Sciences. It has been evaluated in vivo for the treatment of sarcoma M1 [87], epibulbal 
and choroid tumors [88], eye and eyelid related tumors [89], bladder and cervical cancer [90,91]. In a 
clinical trial that included 47 patients composed of 35 women presenting pre-cancerous lesions of 
cervix and 12 women with non-invasive cervical lesions, a Photosens® dose of 0.3 mg/kg was applied. 
Twenty four hours post administration, lesions were irradiated with a light dose between 150 and  
200 J/cm2 at 675 nm. No PDT-related pain was reported. Out of these two subgroups, 94.2% and 
83.4% of the patients, respectively, responded fully to the treatment with complete tumor regression, 
with significant regression for 2.9 and 8.3% of the women. Moreover, the same percentage of women 
showed stabilized disease status. The remaining percentages correspond to the patients who responded 
only partially to the treatment. Today, Photosens® is commercialized in Russia by NIOPIK. 
2.1.4. AlPcS-Conjugation to Tumor Targeting Moieties 
Except for AlPcS1, aluminium sulfonated Pcs are readily soluble in aqueous media. Thus, most 
formulation efforts were aiming at increasing Pc accumulation and uptake by the tumors through the 
increase of the circulation half life or cellular/subcellular targeting. 
The tetraglycine derivative Al(SO2Ngly)4 and a mono-substitued AlPcS4 containing one  
6-aminohexanoic acid spacer (AlPcS4A1) have been exploited for protein conjugation. The conjugation 
of AlS4Pc to monoclonal antibodies (Mab) lead to an enhanced phototoxicity in different cell lines 
such as human colon carcinoma LoVo [92], modified human ovarian carcinoma cells SKOV3-CEA-1B9 
(SKOV cells transfected with carcinoembryonic antigen (CEA) cDNA and expressing two target 
antigens CEA and ErbB2) [60], and various squamous carcinoma cells including UM-SCC-11B,  
UM-SCC-22A, UM-SCC-22B, A431, SCV-7 and OE [56,93]. 
Moreover, in vivo biodistribution studies on tumor bearing mice revealed that these conjugates 
presented an increased selectivity toward the malignant tissues compared to free AlPcS4. Indeed, when 
12 identical Pcs were conjugated to a 35A7 Mab directed against CEA (35A7 Mab-(AlPcS4A1)12),  
a tumor-to-muscle ratio and tumor-to-skin ratio of 33 and 8, respectively, was reported in nude mice 
bearing a human colon carcinoma xenograft [92]. In a subsequent study, the photodyanmic efficiency 
was further improved using an internalizing antibody (FSP77) directed against ErbB2.  
In vitro, SKOV3-CEA-1B9 showed a fast uptake of FSP77Mab-(AlPcS4A1)6 and a higher phototoxic 
efficacy (i.e., 96% vs. 68% of growth inhibition) as compared to the corresponding 35A7 Mab 
(AlPcS4A1)8 [60]. These studies are in agreement with the results reported by Vrouenraets et al. [56,94] 
Pcs conjugated to internalizing Mabs, i.e., SCC-Mab 425 and Mab U36, were photodynamically more 
effective than the corresponding non-internalizing Mab E48. Furthermore, the Mab 425-AlPcS4 was 
7,500 times more effective in vitro than free AlPcS4. It has to be noted also that the loading of PS per 
Mab can be tuned through different conjugation methods. Indeed, by introducing a five carbon spacer 
chain between the Mab and AlPcS4, Carcenac et al. [92] were able to link up to 16 AlPcS4A1 entities to the 
proteins whereas Vrouenraets et al. could only conjugate four Al(SO2Ngly)4 without affecting its solubility. 
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Later, Vrouenraets et al. tested three different Mabs [BIWA 4 (bivatuzumab), E48 and 425] on  
five different SCC cell lines (22A, 22B A431, SCV-7 and OE) [93]. PS conjugation to the 
aforementioned Mabs resulted in a higher phototoxicity compared to free AlPcS4. BIWA 4-AlPcS4 
showed highest phototoxicity in all the five cell lines, exhibiting an IC50 as low as 0.06 nM as 
compared to IC50 ≥ 700nM for the free PS. Interestingly, the effect of the other Mabs varied depending 
on the cell line but not on the internalizing efficiency of the particular Mab. Mab E48-AlPcS4 
conjugate was more active on 22A than on 431 cells, while Mab 425-AlPcS4 conjugate had the 
opposite effect. After determination of Pc’s cell binding and internalization, the authors suggested that 
the phototoxicity of these conjugates was more dependend on the overall cell binding than on their 
cellular internalization. 
Overexpression of the low density lipoproteins (LDL) receptor has been reported for several tumors 
allowing the internalization of LDL proteins into the cell [95]. Therefore, Urizzi et al. [96] conjugated 
AlS4Pc to LDL either via covalent linking of a bisulfonated substituent of AlPcS4 through a 5-carbon 
spacer chain [(AlPcS4A2): aluminium di-(6-carboxypentylaminosulfonyl)-tetrasulfophthalocyanine) or 
non-covalent linking to the phospholipidic region of LDL (AlPcS4(C12)]. Loading ratios of 72:1  
and 61:1 for AlPcS4A2-LDL and AlPcS4(C12)-LDL, respectively, have been reported to be the most 
stable formulations. 
These compounds were tested in vitro on EMT-6 and A549 cells. After 2 h of incubation with the 
conjugates or with free AlPcS4, AlPcS4(C12)-LDL displayed a 10-fold higher phototoxicity effect than 
AlPcS4A2-LDL. This has been ascribed to the increased aggregation tendency, higher scavenging of 
ROS products, and alteration of the conjugate interaction with cellular receptors when Pc was 
covalently coupled to the protein. 
Interestingly, free AlPcS4 and AlPcS4A2 were devoid of any photocytotoxic effects under the same 
conditions. A possible reason for this lack of photoxic activity could be the negative net charge of 
these Pcs, leading to a different cellular uptake and/or intracellular localization.  
Further in vivo studies on mice bearing EMT-6 allografts were performed comparing free AlPcS4 to 
AlPcS4(C12) and AlPcS4(C12)-LDL conjugate. No difference in tumor response was reported for both 
conjugates. As compared to free AlPcS4, 25 times lower drug doses could be used to induce similar 
responses. Moreover, the post-treatment oedema regressed within 3–4 days post-PDT. The similar 
phototoxic effect of free and AlPcS4(C12)-LDL conjugate can presumably be attributed to binding of 
the free Pc to plasma proteins (e.g., LDL) and redistribution post injection. 
Overexpression of gastrin-releasing peptide-receptors (GRPR) have been associated with many 
cancerous conditions such as ovarian, breast, prostate and lung cancer [97]. Since bombesin is the 
amphibian homologue of the human gastrin releasing peptide [98] a recent study reported an attempt to 
target human prostate tumor cells PC-3 by conjugating AlPcS4 to bombesin.  
However, due to the conjugation of bombesin to the AlPcS4 (Figure 4), the binding affinity to 
GRPR was about 40 times lower for the conjugate as compared to bombesin, certainly resulting in a 
loss of specificity and a moderate phototoxicity [99]. Nevertheless, the photoactivity of the conjugate 
was 2.5 and 5 fold higher than AlPcS4A1 and the free tetrasulfonated aluminium phthalocyanine, 
respectively, in vitro. 
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Figure 4. Chemical structure of the bombesin-AlPcS4 conjugate 5 for the targeting of GRPR. 
 
2.1.5. AlPcS4-Formulation using Targeted Delivery Systems 
Simple liposomes are usually unstable upon systemic administration and rapidly cleared from the 
body. However, the incorporation of PEG-derivatized phospholipids in the bilayer of liposomal 
membranes generally prolongs their circulation time. This property of PEGylated liposomes coupled to 
additional tumor targeting moiety such as transferrin was exploited by Gijsens et al. in vitro [100] and  
in vivo [101]. In HeLa cells, expressing approximatively 2 × 105 transferrin receptors per cell [102], 
transferrin conjugated PEG-Liposomes containing AlPcS4 (Tf-Lip-AlPcS4) were 10 times more 
efficient than free AlPcS4 (IC50 of 0.63 μM vs. 6.3 μM, respectively) while non-Tf conjugated AlPcS4 
liposomes (Lip-AlPcS4) were less potent than free PS. Indicating that non-targeted liposomes are only 
poorly taken up and additionally, show only limited release of their content into the cells [100]. 
Initially, the same tendencies were confirmed when these formulations were tested on AY-27  
cells [101]. However, in a rat bladder model using the same cell line no or only moderate accumulation 
of all liposomal formulations was observed. However, pretreatment with a chondroitinase breaking the 
epithelial glycocalyx resulted in a selective retention of Tf-Lip-AlPcS4. On the contrary, free AlPcS4 
was detectable with or without the enzymatic pretreatment of the bladder but with a lower selectivity. 
The reported tumor-to-normal tissue ratio and tumor-to-submucosa/muscle ratio for Tf-Lip-AlPcS4 
were 18:1 and 78:1, respectively. 
Qualls et al. [103] encapsulated AlPcS4 into pH sensitive liposomes using 1,2-di-O-(Z-1′-
hexadecenyl)-sn-glycero-3-phosphocholine (DPPlsC) an acid labile lipid. Moreover, folate-
polyethyleneglycol 3350-distearoylphosphatidylethalonamine (Folate-PEG3350-DSPE) was incorporated 
for targeting of folate-receptors in order to promote the receptor-mediated Pc internalization. The 
liposomes were subsequently tested in vitro on folate receptor expressing human nasopharyngeal 
cancer cells. It was found that DPPIsC-folate liposomes were taken up faster and were 
photodynamically more active than the free AlPcS4 confirming earlier studies with similar liposomes 
on colorectal carcinoma cells C170 cells by Morgan et al. [104]. Moreover, it was shown in vitro that 
the targeting moiety rather than the pH sensitivity of the delivery system dominated the 
photocytotoxicity of the PS [103]. 
2.1.6. AlClPc—SAR 
Modulation of the axial substituents is another way to modulate the pharmacological, 
pharmaceutical as well as optical properties of Pcs. As confimed by Chan et al., Ben Hur initially reported 
Molecules 2012, 17              
 
 
110
that a simple Pc carrying a chlorine as counterion (AlClPc, 6, Figure 5) was photodynamically more active 
than its sulfonated counterparts [79,105]. In order to further improve these compounds systematic studies 
with different alterations of the axial substituents have been undertaken. Decreau et al. [106] reported 
increasing phototoxicity with increasing the hydrophobicity of AlClPc derivatives. Indeed, when 
incorporated into liposomal (Egg Yolk Lecithin based liposomes) or emulsion (Cremophor EL based 
emulsion) formulations, the hydrophobic aluminium Pc (AlPc) derivatives such as 7 and its cholesterol 
derivative 8 (Figure 5) were more phototoxic than 6. After 1 h incubation of achromic M6 melanocytes 
with liposomal formulations of 6 or its derivatives the drug dose required to induce 50% of the cell 
death was 10−8, 3 × 10−8 and 7 × 10−8 M for 8, 7, and 6, respectively. This was further improved by a 
factor of approximatively 10 by using Cremophor EL based emulsions. 
Figure 5. Chemical structure of AlPc 6–10 [106,107]. 
 
Brasseur et al. [107] conjugated polyethylene glycol [PEG; molecular weight (M.W.) of 2,000] or 
polyvinylalcohol (PVA; 13,000–23,000) axially to AlPc (Figure 5). The resulting steric hindrance 
combined with the increased water-solubility provided by the axial polymeric ligands, was expected to 
enhance the efficacy of such AlPc derivatives. In vitro, after 1 h of incubation, the hydrophobic 6 was 
3 times more potent in EMT-6 cells to induce 90% of cell death than its axially derivatized 
counterparts. Interestingly, in in vivo experiments, 10 showed the longest half-life (6.8 h vs. 23 min for 
AlPc-PEG and 2.6 h for 6 in Cremophor EL), the lowest retention in the liver, spleen and lung and 
most importantly the highest tumor accumulation. Tumor-to-skin and a tumor-to-muscle ratios of  
12 and 27 respectively after 24 h post injection in EMT-6 tumor bearing mice have been reported 
whereas, 9 exhibited the lowest half-life and accumulation in tumor. Thus, the axial substitution of 
AlPc with PVA could exert the same efficiency as 6 formulated in Cremophor thereby avoiding 
potential risk factors such as anaphylactic reactions [108]. 
2.1.7. AlClPc-Formulation 
Besides the use of Cremophor EL based emulsions, some efforts have been reported on the 
formulation of AlClPc (6) in suitable delivery vehicles aiming at improving the photodynamic 
outcome of AlClPc-based PDT such as polymeric pH-sensitive micelles. 
Micelles are usually aimed at entrapping hydrophobic drugs in their lipophilic core mostly to 
enhance their bioavailability and to make them suitable for systemic administration. Furthermore, 
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owing the Enhanced Permeability and Retention effect (EPR effect), micelles from 5 to 50–100 nm 
allows the preferential accumulation of drug into tumors [109,110]. Indeed, abnormalities at tumor 
sites i.e., defective and leaky neovasculature, low lymphatic drainage and limited venous return, enable 
drug accumulation and retention in tumors [111,112]. Moreover, pH-sensitive micelles are expected to 
enable specific tumor delivery of the therapeutic agent based on the physiological differences between 
healthy and cancerous tissues [113]. 
It was demonstrated in vitro that pH-sensitive Polymeric Micelles (PM) of N-isopropylacrylamide 
(NIPAM) copolymers loaded with 6 were photodynamically more active than 6 in a Cremophor 
formulation on EMT-6 cells [114]. Furthermore, the terminally alkylated NIPAM copolymers loaded with 
6 were less efficient in vitro than its randomly alkylated counterpart. 
In vivo, 6 encapsulated in PM exhibited a rapid clearance and a low accumulation compared to the 
Cremophor formulation. However, despite these unfavorable pharmacokinetic characteristics, 6 in PM 
showed a “similar phototoxic activity to that of the Cremophor formulation” [115]. 
Trials to decrease PM clearance and thus improve their phototoxicity by incorporating hydrophilic 
N-vinyl-2-pyrrolidone (VP) units into NIPAM copolymers failed; mainly due to increased 
accumulation in the lungs and unchanged uptake by tumor cells [116]. 
The intrinsic insolubility of AlClPc in aqueous media represents certainly a drawback if systemic 
administration of the drug is desired. However, in case of topical application, for the treatment of  
non-melanoma skin cancer the aggregation of the Pc can be circumvented by the use of 
pharmaceutically acceptable solvents that both enable the dissolution of the drug and additionally 
enhance the permeability of the skin such as DMSO [117]. In a study conducted by Kyriazi et al. [118], 
AlClPc was diluted in a mixture of DMSO, Tween 80 and water and tested on albino mice (SKH-HR1) 
and SKH-HR2 (with melanin) bearing UV-induced skin carcinomas. Irradiation was performed both 
on the tumor and also on the normal skin surrounding the tumor. Optimal tumor response in terms of 
“highest percentage of mice in complete remission” was obtained, with a light dose of 150 J/cm2 and a 
fluence rate of 75 W/cm2. Furthermore, the formulation enabled a 40 times more selective uptake of 
the drug by the tumors compared to normal skin after 1 h post-administration. Interestingly, better 
therapeutic outcome was achieved when lower fluence rates were applied. This observation is in 
agreement with other studies conducted on mTHPC and 5-ALA photosensitisers and was related to the 
lower consumption of oxygen under these conditions [119,120]. 
2.2. Zinc Based Phthalocyanines 
2.2.1. ZnPc—SAR 
As mentionned in Section 2.1.1, providing permanent negative charges through sulfonation to Pcs 
increases their solubility in aqueous media. Wöhrle et al. reported [121] that amphiphilically sulfonated 
ZnPcs such as the mono- and disulfonated phthalocyanines are more potent and effective than their tri- and 
tetrasulfonated counterparts in vivo. Comparing Zn and Al substituted analogs, they found the following 
pattern of photodynamic efficacy: AlPcS2 ≈ ZnPcS1 > AlPcS1 > AlPcS3 ≈ ZnPcS2 > AlPcS4 > ZnPcS4.  
In 1997, Kudrevich et al. [122] conducted in vitro and in vivo experiments on Balb/c mice bearing EMT-6 
tumors using a series of trisulfonated, amphiphilic water-soluble ZnPc derivatives (Figure 6). 
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Figure 6. Structures of compounds 11, 12 and 13 [122]. 
 
In vitro compounds 11 and 12 were two and more than five times more potent than the tri and 
tetrasulfonated zinc phthalocyanines, respectively, whereas compound 13, exhibited the lowest 
phototoxicity probably due to its poor cellular uptake caused by the “bulky diphenylpyrazino 
substituent”. In vivo, no tumor regression could be noticed with 13 and ZnPcS3. However, in almost 
90% of the mice treated with 5 μmol/kg of compounds 11, 12, and ZnPcS4 no palpable tumors have 
been detected three weeks post-PDT. It was suggested that the amphiphilic character of 11 and 12 
decreases the aggregation tendency, thus increasing photoactivity and tumor uptake. Moreover, due to 
the higher conjugation extent, a bathochromic shift of the Q-band (i.e., 706 nm) was induced. 
Based on the experiments evaluating the impact of amphiphilicity on photodynamic activity with 
aluminium sulfonated phthalocyanines, there have been numerous attempts to increase the amphilic 
character of zinc sulfonated phthalocyanines. In one of their studies, Cauchon et al. [123] compared 
the photodynamic efficiency of different trisulfonated phthalocyanines bearing one alkyl chain 
containing between n = 2 and 16 carbon atoms (ZnPcS3(Cn)). 
In vitro studies revealed that ZnPcS3(C9) exhibited the highest cellular uptake and photocytotoxic 
effect on EMT-6 cells, while the other hydrocarbon substituted phthalocyanines were less efficient. 
The structure-activity relationship to induce 90% cell death of these compounds followed a typical 
hyperbolic curve also observed for other homologous series of photosensitizers [124]. However,  
the most potent compound in this study was the disulfonated zinc phthalocyanine with two sulfonic 
groups positioned adjacently despite a lower cellular uptake which can be explained by different 
intracellular localization upon internalization. 
In a series of different ZnPcs, disulfo-di-phthalimidomethyl zinc phthalocyanine (ZnPcS2P2 = 14) 
(Figure 7) has been shown the highest photodynamic activity in Human myelogenous leukemia HL60 
cells, K562, FGC85, SGC7901 and LCC carcinoma cell lines [125-127]. Moreover, when administered 
to mice bearing S180 and U14 solid tumors [126] in a Cremophor-based emulsion, the tumor weight in 
PDT treated animals decreased compared to the controls. The highest inhibitory rate was achieved with 
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a drug dose of 2 mg/kg in both models. Moreover, no acute toxicity was reported after intravenous or 
intraperitoneal administration of 14 with drug dose up to 100 mg/kg [126]. The repeated-dose toxicity 
of this compound was assessed a few years later in healthy Wistar rats [128] using the same delivery 
system. Interestingly, an acute toxicity of 14 was found at a dose of approximatively 52 mg/kg  
based on their investigations on mice [126] and on an “anticipated human clinical application”  
(data not disclosed). 
Figure 7. Chemical structure of phthalocyanine 14 i.e., ZnPcS2P2. 
 
It was reported that a 10 times repeated administration of 4 mg/kg, which corresponds to 100 times 
that anticipated clinical “therapeutic” dose by the authors, induced notable hepatic and spleen damage. 
Besides sulfonation, another means to enhance the solubility of Pcs in aqueous media and increase 
their amphiphilicity is hydroxylation. Boyle et al. [129] and Hu et al. [130], reported the synthesis and 
evaluation of several hydroxysubstituted zinc phthalocyanines. 
When incorporated in Cremophor EL emulsions, all compounds showed strong photodynamic 
action both in vitro and in vivo except for the directly substituted tetrahydroxyphthalocyanine 15 (Figure 8). 
Indeed, Boyle et al. [129] showed that 15 was phototoxic in vitro on Chinese hamster lung fibroblasts V79; 
but failed in vivo on Balb/c mice bearing EMT-6 tumors, to induce any perceptible tumor response. 
Meanwhile, the tetra(3-hydroxypropyl) zinc phthalocyanine 16 (Figure 8) and tetra(6-hydroxyhexyl)zinc 
phthalocyanine 17 (Figure 8) induced tumor cure as measured by tumor necrosis within 48 h and no 
tumor regrowth up to 30 days at 0.5 μmol/kg and 1 μmol/kg (1.0 mg/kg), respectively, when applied 
intravenously. Compared to a mixture of mono, di, tri and tetrasulfonated ZnPcs, 16 and 17 were ten 
and five times more potent than ZnPcS. Furthermore, it seemed that the hydroxyderivatives function 
via vascular shutdown rather than direct cell killing as observed for the sulfonated zinc phthalocyanines. 
Molecules 2012, 17              
 
 
114
Figure 8. Chemical structure of hydroxylated phthalocyanines 15–21. 
 
Moreover, Winkelman et al. [131] postulated that a critical distance of 1.2 nm is required between 
oxygen atoms of sulfonate, carboxyl or hydroxyl substituents and the core of phthalocyanines or 
porphyrins in order to present biological activity. This hypothesis could potentially explain the low 
photoactivity exhibited by 15 as well as the phototoxicity of the alkylhydroxy ZnPc derivatives. 
A few years later, Hu et al. [130] tested mono-, di- and tri-substituted hydroxy ZnPcs derivatives 
18–21 (Figure 8) formulated in Cremophor emulsions in EMT-6 tumor cells in vitro and in vivo. It was 
observed that the phototoxicity decreased with the introduction of hydroxyl groups (i.e., 15 vs. 20) and 
that adjacent positioning of the hydroxyl functions such as in 21 increased Pcs phototoxic effect.  
A third possible chemical modulation of ZnPc consists in fluorination of the PS. Several articles 
report the synthesis and evaluation of this class of ZnPcs [132,133] (Figure 9). The main reasons being 
that fluorination increases the water solubility and triplet state quantum yield of the phthalocyanine 
while maintaining similar behavior in biological medias as hydrogen atoms [134]. 
The most extensive studies on fluorinated ZnPc in PDT have been performed by the van Lier group 
(using hexadecafluorinated zinc phthalocyanine (ZnPcF16)(25, Figure 10) [135-138]. 
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Figure 9. Structure of the fluorinated ZnPc 22, 23 and 24. 
 
Figure 10. Structure of the zinc hexadecafluorinated Pc 25 and its monosulfonated analogue 26. 
 
In their most recent publication on this subject, Allémann et al. [137] compared Cremophor based 
emulsion of compounds 25 and 26. It is noteworthy to mention that Pc 26, bears one sulfonated group 
to provide some amphiphilicity, thus, probably improving cell penetration. To BALB/c mice bearing 
EMT-6 tumor allografts, 1 μmol/kg of 25 or 26 were applied and their bioavailability as well as their 
PDT effect has been assessed. After one week, the area under the plasma concentration as a function of 
time of 25 and 26 were 237 and 183 nmol·h/g with half-lives of 9.25 and 12 h, respectively.  
The highest PS tumor accumulation was recorded 24 h post-injection for both Pcs. However,  
26 exhibited better tumor selectivity with reported tumor-to-muscle and tumor-to-skin ratios of 
approximatively 13 and 4 for 26 and, 7 and 2.5 for 25, respectively. Strikingly, a 66% tumor response 
was recorded for 26 at 1 μmol/kg for a light dose of 100 J/cm2 but was associated with 33% mortality. 
Hence, it was considered that the best PDT results (i.e., tumor response and animal viability) were 
obtained using 0.1 μmol/kg of 26 irradiated at 400 J/cm2. As compared to previous results reported by 
Boyle et al. [138], 26 is twenty times more phototoxic than 25 while displaying equivalent tumor 
uptake. The impressive 26 phototoxicity observed was attributed to “extensive cellular damage”.  
In tumor free rats, 26 formulated in Cremophor was devoid of any lethality after irradiation. 
Alterations of tumor surrounding tissues and extensive edema were reported, but were associated with 
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rapid recovery [137]. A proposed way to avoid these collateral damages is to tune its biodistribution 
and elimination using different formulations forms, such as PEG-coated nanoparticles (NP). In Section 
2.2.3 of this review, formulation of 25 in NP is further discussed. 
Allémann et al. [137] also investigated the influence of incubation media on PDT efficiency of 
ZnPc in vitro by comparing 1-methyl-2-pyrrolidinone to pyridine. Dilution of Cremophor emulsion of 
ZnPc at 10 μM in 1-methyl-2-pyrrolidinone solution led to complete loss of in vitro PDT efficacy 
presumably due precipitation and aggregation as noticed by an altered absorption spectrum.  
This observation confirmed earlier in vivo studies by Boyle et al. [138] that obtained no significant tumor 
response in BALB/c mice bearing EMT-6 tumors when ZnPc was diluted in 1-methyl-2-pyrrolidinone. 
In the meantime, complete tumor ablation was achieved when pyridine was used to dilute ZnPc 
Cremophor-based emulsion at a drug dose of 2 μmol/kg. The authors assumed a possible “coordination 
of pyridine to the axial ligands of the central metal ion” resulting in an increase photodynamic activity. 
Choi et al. and Liu et al. [139,140] reported recent in vitro investigations on the influence of 
glycosylated ZnPc based on the strategy to concomitantly increase the water-solubility and the 
selectivity of these compounds through targeting of glucose transporter [141,142]. In accordance with 
zinc sulfonated phthalocyanines, tetra-glycosylated ZnPc derivatives were substantially less 
photoactive than the mono-glycosylated and di-glucosylated ZnPcs derivatives in vitro [139,140]. 
Moreover, the  and  positioning of the glycose substituents seemed to influence the tendency to 
aggregate and consequently affects their phototoxicity. Indeed,  substitution appeared to prevent Pc 
aggregation as compared to the  positioned analogues. Promising phototoxicities in the nanomolar 
range were achieved in HT29 and HepG2 cells glucosylated di-  substituted ZnPc. 
Ometto et al. [143] as well as Fabris et al. [144] have tested octapentyl (27) and octadecyl (28) 
substituted ZnPc (Figure 11). Administered intramuscularly to MS-2 fibrosarcoma bearing Balb/c mice 
in a Cremophor emulsion both compounds were highly selective for the tumor tissue. Limited skin 
photosensitization was confirmed with healthy Balb/c mice under the same experimental conditions. 
The strong binding of both compounds to LDL is presumably responsible for this selectivity [145]. 
Both 27 and 28 induced a shrinkage of the tumor volume after PDT [143,144]. However, both 
derivatives accumulated to a higher extend in the liver and spleen than in the tumor even one week 
post-PDT, presumably because the bile-gut is the primary elimination pathway characteristic for lipidic 
drug delivery systems [143,146].  
Figure 11. Chemical structure of octapentyl and octadecyl ZnPcs 27 and 28. 
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Liu et al. have achieved synthesis and in vitro evaluation of zinc octa[(biscarboxylate)-
phenoxy]phthalocyanine and its sodium salts [147] (i.e, compounds 29 and 30, see Figure 12). 
Figure 12. Chemical structure of phthalocyanines 29 and 30. 
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This structural extension with phenylcarboxylate groups resulted in a diminished stacking and 
aggregation tendency, due to possible non-planar orientation of this group as well as extended  
“inter-ring distance”. However, at physiological pH, only 29 was water-soluble. The authors presented 
this aspect as the major drawback of 29 to HEp2 cell penetration, whereas the more hydrophobic 30 
was taken up to a higher extent. However, cell penetration could have been also hampered by the 
presence of negative charges on 29 at physiological pH. Despite differences in cellular uptake both Pcs 
displayed similar but moderate phototoxicities. However, this low potential for photosensitization of 
biological materials can be efficiently used for fluorescence diagnostics. Very recently ZnPc similar to 
29 zinc tetra[(monocarboxylate)phenoxy]phthalocyanine has been exploited for the use in PCR 
analysis [64]. This compound had similar but narrower absorption and emission bands in the NIR as 
compared to a conventional cyanine dye. Most importantly, the Pcs dyes were thermally and 
chemically stable and showed essentially no photobleaching. 
The outstanding tendency of Pcs to form photoinactive aggregates can also be exploited for the 
design of “molecular beacons”. These compounds are powerful tools for real time detection of 
RNA/DNA in vitro and in vivo. In molecular beacons, a quencher/donor pair is positioned on the distal 
ends of a short, hairpin forming oligonucleotide. In absence of a complementary sequence the close 
proximity of the fluorophore and its corresponding quencher makes the molecular beacon optically 
silent. However, hybridization with the complementary sequence then restores the fluorescence of the 
reporter. Despite their high specificity the sensitivity of conventional molecular beacons is often 
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compromised by a poor sensitivity provided by insufficient quenching. Futhermore, longer observation 
periods are often impeded by most fluorescent dyes’ strong photobleaching. Therefore, in an earlier study 
the same group reported the use of a pair of Pc similar in structure to ZnPc in molecular beacons [148,149]. 
After optimization of the reaction conditions good yields for molecular beacons were achieved. 
However, since Pcs have long interaction ranges the authors had to use longer oligonucleotide 
sequences as complementary sequence to observe a fluorescence increase. A signal to background ration 
as high as 59 was reported. Furthermore, the perfect matched complementary sequence was five times 
more fluorescent than a single base mismatch. Therefore, water soluble Pcs can be efficiently employed 
as fluorescence reporters in vitro but their whole potential in this area remains to be demonstrated. 
Lo and co-workers reported the photoactivity of monosubstituted ZnPc with a 1,3-bis(dimethyl-
amino)-2-propoxy group at the α or β position (Figure 13), “and the corresponding di-N-methylated 
derivatives” on human colorectal carcinoma cells HT29 [150]. The  and  positioning is an analogy 
to the  and  positions for sugar moieties. Indeed in sugars,  and  correspond to lower and upper 
position respectively of the hydroxylic group on the anomeric carbon (C1) of the cyclic sugar moiety, 
the cylcle defining the referential plane [151]. 
Figure 13. Structure of compounds 31–34. 
 
The absorption and fluorescence spectra showed a lower aggregation tendency for the -substituted 
compounds as compared to their -substituted analogues. Consequently, the IC50 of 32 and 34 were 
0.15 and 0.08 μM, respectively, while 31 and 33 induced 50% of cell inactivation at doses of  
0.48 and 0.64 μM, respectively.  
Like AlPcs, PEGylated ZnPcs have also been designed aiming at increasing their water  
solubility [152]. Liu et al. have prepared a series of asymmetrically substituted ZnPcs using 
methylated polyethylene glycol. However, these compounds were essentially not water soluble. 
Therefore, just recently the synthesis of tetra and octa substituted PEGylated ZnPcs has been  
reported [153]. In these compounds the terminal methyl group of the tetraethylene glycol side chains 
has been omitted in order to provide a higher hydrophilicity through hydroxyl end groups. Despite 
these modifications, aggregation in water was still observed that could be circumvented by the addition 
of Triton-X100. The less aggregated compound that was non-peripherally substituted with 
polyethylene glycol showed a strong bathochromic shift of more than 20 nm. But in vitro evaluation 
showed an IC50 value that was in the order of two orders of magnitude higher than reported for the 
methylated counterparts. Recently, Ng and co-workers reported the synthesis and efficient 
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photocytotoxic effect of several pegylated ZnPcs where IC50 values ranged from 0.25 to 3.72 μM on 
HT29 and HepG2 cells [154]. 
The net charge of pharmacological compounds is of importance with respect to the pharmacokinetic 
properties of a drug as well as in terms of uptake and intracellular localization. Several studies report 
the impact of the charge on Pc-mediated PDT. Banfi et al. [155] described the synthesis and in vitro 
assessment of some ZnPc derivatives on human colon adenocarcinoma cells HCT116. The most potent 
ZnPc derivatives among the synthesized series are shown in Figure 14. 
Figure 14. Structure of compounds 35, 36 and 37. 
 
Compound 35 was approximately five times more potent than compound 36 and approximately 
eight times more efficient than compound 37. 
Brown and coworkers [156,157] reported that the cationic pyridinium ZnPc 42 (see Figure 15) was 
more phototoxic to RIF-1 cells than the anionic tetraglycine analogue 39 or the neutral hydrophobic 
tetradioctylamine 43 [156]. In vivo all the tested compounds induced partial tumor regression, but only 
compound 42 led to complete remission, most presumably through vascular occlusion in the irradiated 
areas. This observation is in agreement with a study of Sibrian-Vazques et al. that showed that the 
cellular uptake of 44 was higher and faster than 46 (see Figure 16) [158]. 
Figure 15. Chemical structure of phthalocyanines 38–43. 
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Figure 16. Chemical structure of compounds 44–48. 
 
2.2.2. Tumor Targeting with Zinc Based Pc-Conjugates  
In the same report the preparation and in vitro evaluation of zinc based phthalocyanines conjugates 
with cell-penetrating peptides (CPP) (see Figure 16) was described. 
Conjugates 47 and 48 were taken up by HEp2 cells to a higher extent than the unconjugated ZnPc. 
The introduction of short polyethylene glycol linker between the ZnPc and CPP has been shown to 
further increase the uptake. At a light dose of approximately 1 J/cm2, 47 and 48 were the most active 
compounds, with IC50 values of 1.44 μM, 1.87 μM, respectively. In contrast, 44 did not alter the cell 
viability at doses up to 10 μM.  
2.2.3. Formulation of ZnPcs 
Phototoxicity and fluorescence of Pcs is mostly hampered by their low water-solubility and 
tendency to aggregate. Their incorporation into suitable and biodegrable formulations is commonly 
accepted as a necessity in the development of new therapeutics. Indeed, development of drug delivery 
systems such as liposomes, micelles and nanoparticles could improve the unfavorable biodistribution 
of free Pcs (i.e., improvement of PS pharmacokinetic properties, better targeting of diseased tissues 
due to size of the particles, association to serum proteins and specific activation of the PS through 
localized delivery of the PS) as well as avoidance of aggregation and loss of phototoxic 
activity/fluorescence which should result in a better therapeutic outcome (see following paragraphs).  
Zinc based phthalocyanines have been mostly evaluated as liposomal formulations. Liposomes are 
phospholipids vesicles that present the advantage to entrap either hydrophilic drugs in the core of the 
phospholipid vesicle or hydrophobic drugs within the lipid membrane. Incorporation of drugs into 
liposomes results in passive targeting of tumors [159,160]. In studies reported in this review, only 
small unilamellar vesicles (i.e., one phospholipid bilayer) were used. 
Liposomal formulation of ZnPc showed photocytotoxic effect in vitro on a large variety of tumor 
cell lines [161-163]. The drug CGP55847 commercialized by CIBA has been the first Pc reaching 
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clinical trials although no clinical results have been reported. Ben-Hur and Chan reported that the 
“early phase I/II clinical studies […] were discontinued but not for medical reasons” [164]. 
In vivo, ZnPc being incorporated in dipalmitoyl-phosphatidylcholine (DPPC) liposomes showed 
complete response at drug doses as low as 0.14 mg/kg in mice inoculated with MS-2 fibrosarcoma.  
At a slightly lower dose of 0.12 mg/kg (i.v.), ZnPc was found to be “associated exclusively with 
lipoprotein fraction”, i.e., whether it was complexed with low density lipoproteins (LDL) or 
incorporated into liposomal structures, and 70% of the drug was cleared from the body within 12 h 
independently from its carrier system, while the remaining ZnPc was slowly eliminated. However, 
ZnPc associated with LDL presented a higher selectivity toward tumor than ZnPc liposomes with a 
tumor-to-liver ratio of 2.27 and 1.04 and a tumor-to-muscle ratio of 4.20 and 3.84 after 24 h  
post-injection, respectively. Nonetheless, the selectivity was somewhat limited by the redistribution of 
the photosensitizer among other lipoproteins, especially high density lipoproteins. As liposomal 
formulations of benzoporphyrin derivative, liposomal CGP55847 seems to be transferred to serum 
lipoproteins and more predominantly to low density lipoproteins [165-169] explaining the propensity 
of the PS to selectively accumulate in tumors [163,170]. Rodal et al. suggested that the observed 
internalization of ZnPc was not following the endocytotic pathway of LDL but rather occurred via 
diffusion through the cellular membrane after binding to the LDL receptor [161]. 
In vivo studies on different liposomal formulations consisting of a mixture 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (OOPS) revealed that 
intratumoral distribution pattern of ZnPc in C57BL/6 mice bearing Ehrlich carcinomas or B16 melanomas 
was a time dependent process [171]. In agreement with van Leengoed et al. [172], 3 h after intravenous 
injection of 0.5 mg/kg of ZnPc, the photosensitizer was present in and around the tumor vasculature 
but not 24 h post-injection. Indeed, using a dorsal skinfold chamber model, van Leengoed et al. [172], 
could detect vascular occlusion within five minutes after photoactivation which resolved 30 min after 
irradiation. Moreover, maximal vasculature damage and tumor-to-muscle ratio from 8:1 to 14:1 have 
been reported for this liposomal delivery system [173]. 
Nanoparticles are another type of drug delivery system that enables the incorporation of higher drug 
doses of hydrophobic drugs. Passive targeting of tumors is also achieved due to their size (i.e., below 
1,000 nm, generally 200 nm) through EPR effect. A strategy to increase the circulation time of the 
nanoparticles as well as other drug delivery systems is the incorporation of PEG moieties on their 
surface. It is commonly accepted that PEGylation creates hydrophilic barrier that reduces the 
immunogenicity of the drug delivery system and lowers its clearance from the body [174-176]. 
Polylactic acid (PLA) based nanoparticular formulations of ZnPc were investigated by  
Allémann et al. [135,136]. The coating of nanoparticles with PEG moieties resulted in the decrease of 
the reticuloendothelial system and an increase in the PS tumor retention [135]. Incorporation of 25  
(Figure 10) into PEG coated nanoparticles or using a Cremophor EL based emulsion increased the 
bioavailability as compared to uncoated-NP by a factor of four in BALB/c mice bearing EMT-6 
tumors. The tumor-to-skin and tumor-to-muscle ratios for the PEG-NP and Cremophor based 
formulation were 2 to 21, respectively, with a maximum concentration in tumor 48 h post-injection [135]. 
However, the nanoparticular drug delivery system was nearly five times more efficient for  
PDT-mediated treatment of mice bearing EMT-6 tumors [136]. This is in agreement with a study 
reported by Fadel et al. [177] describing that tumor bearing animals treated with ZnPcs laden 
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poly(lactic-coglycolic acid) nanoparticles showed the best PDT outcome, highest tumor growth delay 
and longest survival times as compared to mice treated with the free PS.  
An interesting approach was recently described by Kataoka and co-workers [178-181] where 
dendrimer based zinc phthalocyanines showed promising results in PDT and PCI applications. Indeed, 
they could manage to prepare anionic dendrimer zinc phthalocyanine (DPc) incorporated into 
positively charged poly(ethylene glycol)-poly(L-lysine) (PEG-PLL) block copolymeric micelles 
referred to as polyion complex micelles (PIC) [180]. The substitution of large dendritic parts avoids 
the aggregation and increases their water solubility [181]. These micelles were tested both in vitro on 
human lung adenocarcinoma cells A549 and in vivo on (Balb/c nu/nu) mice bearing A549 tumors.  
It was shown that 7.6 times more of encapsulated DPc in micelles (DPc/m) was taken up and that these 
are 78 times more phototoxic in vitro than free DPc. In addition, subsequent in vivo studies confirmed 
the benefits of micelle encapsulation of DPc by delayed tumor growth and limited skin photosensitization. 
Another interesting approach for drug delivery of hydrophobic PS is their conjugation to 
cyclodextrins. This strategy enables the water-solubilisation of lipophilic PS and thus its systemic 
administration at high concentrations. In one report, Baugh and al. proceeded to the conjugation of zinc 
based phthalocyanines to cyclodextrins. The double carbon bounding linkage between the dimers was 
cleaved, upon light activation and in presence of oxygen; resulting in the release of the Pc. Hence, this 
approach could be a promising systemic carrier of hydrophobic PS for photodynamic therapy [182,183]. 
Formulation of ZnPcs in gels or (micro)emulsions could be of interest in topical application. Indeed, 
several studies reported improved photophysical and aggregation properties of ZnPcs [184,185] as well 
as successful delivery to the skin of sulfonated ZnPc either via simple skin penetration [184] or 
through iontophoresis [186]. 
2.3. Silicon Based Phthalocyanines: Pc 4 and its Analogues 
2.3.1. SiPc-SAR 
Several silicon based phthalocyanines (SiPc) mostly aiming at revealing the influence of axial 
ligands have been proposed and tested both in vitro and in vivo. Probably, the most famous 
representative of these compounds with some commercial value is “La Jolla Blue”. Water-solubility of 
this dye absorbing at 680 nm as well as prevention of aggregation is provided by two axial 
polyethylene oxide moieties. Then, two peripherial carboxy groups at the macrocycle can be used for 
the coupling to biological molecules such as antibodies. This has been used for the design of an 
antibody for an FDA cleared in vitro immunofluorescence assay.  
It has been shown by He et al. [187], that silicon based phthalocyanines with short aminosiloxy 
ligands [49 (Pc 4) and 51] are more phototoxic effect in Chinese hamster lung fibroblasts V79 and 
Murine leukemic lymphoblasts L5178Y-R as compared to compounds such as 50 and 52 with longer 
axial ligands (see Figure 17). 
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Figure 17. Chemical structure of Pc 4 (49) and derivatives 50–58 [187-194]. 
 
In another report [194], the PDT effects of these compounds in vivo on C3H/HeN mice bearing 
RIF-1 tumors were examined. The phthalocyanines were solubilized in a Cremophor EL emulsion and 
light was given 24 h post Pc injection. Except 52, all axially substituted Si-Pc resulted in a complete 
remission. The authors suggested that 51-mediated PDT may induce cellular destruction via a slower 
mechanism than Pc 4-mediated PDT. 
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In 2009, Rodriguez et al. [188], compared Pc 4 to compounds 51, 53, 54 and 55 on the human 
breast cancer cell line MCF-7c3. These analogues showed, among other features, higher cellular 
uptake and phototoxicity than Pc 4. Biaxial substitution reduced aggregation which, in turn, can 
explain their higher photodynamic efficiency. Furthermore, the presence of a hydroxyl group at one 
side seems to enhance the phototoxicity of the SiPcs. However, as shown by confocal microscopy, 
except for 51, Pc 4 analogues seem to act through a different destructive pathway due to their principle 
association with lysosomes rather than with mitochondria/endoplasmic reticulum. Interestingly, when 
clonogenic assays were performed 51 and Pc 4 had a similar behavior. In contrast, 51 exhibited a  
4-fold lower IC50 in comparison to Pc 4 (49) as demonstrated by means of a MTT test. Using bi-axially 
substituted polyamine SiPcs with fluorescence quantum yields in aqueous media of 0.12–0.21, IC50 
ranging from 450 to 1 nM have been reported in HT29 cells by Ng and co-workers [195]. 
Moreover, the same group of research developed several SiPcs substituted axially with  
-cyclodextrins [196-198]. They could reach a photocytotoxic effect on human colon adenocarcinoma 
and hepatocarcinoma cells (HT29 and HepG2 respectively) with reported IC50 ranging from 21 nM to 
1.32 M. In addition, early in vivo studies conducted by Lau et al. [197] show promising results as 
drug doses as low as 1 mol/kg for a light dose of 30 J/cm2 are efficient enough to suppress tumor 
growth in mice bearin HT29 xenografts. 
Another promising approach used by the same group is the glucoconjugation of SiPcs [190,199].  
In their report, Chan et al. [199] reported IC50 values as low as 6 nM on the same cell lines and could 
“retard tumor growth” in the same animal model. 
Pc 4 has been developed at Case Western Reserve University at the beginning of the 90s. Since then 
Pc 4-mediated PDT has been reported effective in vitro against various tumor cell lines of different 
origin [187,200-205]. In experimental animal models for ovarian and colon cancer, no photodynamic 
effect was observed with doses of 0.4 mg/kg [202], whereas with doses of 0.6 or 1 mg/kg complete 
remission or at least significant tumor volume reduction occurred between 3 to 7 days post-PDT. 
Furthermore, Pc 4-PDT was associated with a delay of tumor regrowth from 9 [203] up to 90 days [202]. 
A recent study conducted on immunideficient mice bearing papillomas [206] induced by the 
administration of cottontail rabbit papillomavirus led to the conclusion that Pc 4 at a dose of 1 mg/kg 
and at a light dose of 150 J/cm2 given 48 h administration resulted in complete remission in 87% of the 
cases with no observable re-growth during 79 days. In addition, it was suggested that the rapid 
destruction observed in Pc 4-mediated PDT could be explained by the mitochondrial/endoplasmic 
reticulum [188] localization of Pc 4 mainly leading to apoptosis and necrosis [207-209]. However in 
some cases vascular occlusion was also reported [188]. 
Moreover, Anderson et al. [210] demonstrated that Pc 4 exhibited less skin photosensititization as 
compared to Photofrin®. Topically applied, Oleinick and co-workers established that Pc 4 is 
“effectively delivered into the human skin” [211] and was consequently investigated clinically.  
In these trials, Pc 4-mediated PDT was reported to be well tolerated in patients and could have 
promising application in mycosis fungoides treatment [212]. 
Recently, Fong and coworkers reported the synthesis and characterization of several silicon-based 
phthalocyanines [189,213-217]. Out of this series, BAM-SiPc 56 (see Figure 17) having an IC50 as low 
as 0.015 μM on HepG2, Hep3B, HT29 and J744 was the most potent. However, this compound was 
phototoxic on normal liver cells (i.e., WRL-68 with IC50 of 0.035 microM under the same experimental 
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conditions) [189,192,218]. In nude mice bearing hepatocarcinoma HepG2 and colorectal 
adenocarcinoma HT29 tumors the same compound showed remission/regression and tumor growth 
delay 15 days after PDT at a drug dose of 1 μmol/kg [191]. 
Barge et al. [193] could also covalently link axial cholesterol moiety (Chol-O-SiPc) (Figure 17) and 
reported a seven fold higher potency of this derivative as compared to AlClPc (with IC50 of 
approximatively 8 nM) in vitro, on the pigmented melanoma cell lines M3Dau and SK-MEL-2. 
2.3.2. SiPc Formulations 
Pc 4 is the most extensively studied silicon-based phthalocyanine. Due to its insolubility in 
physiological media, Pc 4 tends to aggregate with subsequent loss of photodynamic activity and altered 
biodistribution. In order to avoid these issues, Pc 4 was incorporated in oil-based formulations,  
PEG-PCL (polyethylene glycol-block-poly--caprolactone), micelles, and nanoparticles. 
In a recent study Master et al. [219] were able to encapsulate with 70% efficiency Pc 4 in PEG-PCL 
micelles. The authors observed that in human breast cancer cells (MCF-7c3), Pc 4 delivered in  
PEG-PCL micelles seemed to colocalize with lysosomes and mitochondria, while Pc 4 in solution 
accumulated mainly in mitochondria and endoplasmic reticulum as well as in Golgi apparatus. 
However, no different photocytotoxic effect was observed for the two formulations. 
Pc 4 was also encapsulated into silica and gold nanoparticles known for their biocompatibility and 
their stability [220]. Zhao et al. [221] showed that encapsulation into silica nanoparticles of 25–30 nm 
diameter lead to enhanced photodynamic activity in vitro as compared to the free Pc 4. Moreover,  
Pc 4 silica nanoparticles were found to be less sensitive to photobleaching. The reported IC50 values for 
the nanoparticluar delivery system were around 5 nM for A375 cells and 10 nM for B16F10. 
An in vivo biodistribution study with Pc 4 adsorbed on PEG coated gold nanoparticles revealed that 
Pc 4 gold nanoparticles accumulated in the tumor faster than Pc 4 formulated in Cremophor EL. While 
the peak concentration in the tumors was only reached after 2 days using Cremophor the gold 
nanoparticles containing Pc 4 reached this peak within 2 h. It was also observed that the singlet oxygen 
yield of the two formulations was identical suggesting that the nanoparticles protect Pc 4 until its 
release in the target tissue [222]. 
Li et al. reported the synthesis and PDT effect of a neutral and lipophilic tetra-t-butyl silica 
phthalocyanine bisoleate referred to as SiPc-BOA (Figure 17) [223]. It was noticed that axial 
substitution of the oleate moieties decreased the propensity of the photosensistizer to aggregate and 
enabled its binding to the lipidic layer (i.e., LDL delivery system). Using this strategy, Li et al. 
increased the loading of the LDL nanovesicules with a molar ratio of 400 SiPc-BOA per one LDL [223]. 
These SiPcBOA laden nanoparticles were 10 times more effective than the free compound in HepG2 
cells suggesting a LDL receptor-mediated photodynamic effect.  
A multifunctional approach was proposed by Zheng et al. [224] through additional coupling of folic 
acid to lysine residues of the apolipoprotein B of the LDL part in SiPc-BOA-LDL conjugates.  
The validity of their hypothesis was tested in a system consisting of cells expressing the folate receptor 
(κB cells), those expressing the LDL receptor (HepG2 cells), and cells that lack the folate receptor 
(HT1080, CHO cells). An interesting review of the aforementioned results could be found in the 
following book [225]. 
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3. Applications of Pcs in Fluorescence Imaging 
Most investigations on phthalocyanine dyes in biomedicine focus on their application in PDT for 
cancer. However, just recently research was also extended to parasite and bacterial disease treatment 
such as leishmaniosis [226-230]. Furthermore, in this context, an at least as important research area, 
i.e., fluorescence imaging, is sometimes ignored. Fluorescence imaging allows the non-invasive 
detection of superficial disease in a preclinical or clinical setting. It is sensitive, can be perfomed in 
real time, and its resolution can be tuned to a molecular level. As few as a thousand cells can be 
detected by this methodology. Today, fluorescence imaging is successfully implemented in preclinical 
in vitro and in vivo research to specifically monitor the therapeutic outcome of new drugs in animals or 
to reveal disease mechanisms. Furthermore, it is used clinically for the detection of several diseases, 
including age-related macular degeneration [231] and cancer [232]. It has been shown to improve the 
detection rate of barely visible lesions, surgery and recurrence rate in malignant glioblastoma [233,234] 
and bladder cancer [235]. Despite the recent hype of fluorescent proteins introduced into molecular 
biology, exogenous fluorescent dyes [236,237] or exogenously-induced fluorescent dyes [238] still 
play an important role in this research area. 
For optimal monitoring of diseases in vivo it will be advantageous that fluorescent dyes absorb and 
emit in the NIR region of the visble light spectrum in order to optimally penetrate into the tissue and 
induce only minimal autofluorescence upon excitation with light. Therefore, scientists have developed 
panoply of different NIR fluorescent dyes for the labeling of proteins, small bioactive peptides,  
or oligonucleotides [239]. Although there are many classes of NIR dyes including oxazines and 
rhodamines commercially available, the most commonly used belong to the class of cyanine dyes.  
One of these, indocyanine green, is approved for the detection of occult choroidal neovasculariuation 
secondary to age-related macular degeneration. Today these dyes cover an absorption spectrum 
ranging between 650 and 800 nm. As described above, phthalocyanine dyes can be fine-tuned to the 
desired absorption/emission wavelengths and can be made water-soluble [240]. Furthermore, they are 
chemically stable in most solvents and are not as prone to degradation in highly acidic/basic media. 
Some of these compounds can have a fluorescent quantum yield as high as 70% and are extremely 
photostable. And finally, compared to conventional cyanine dyes they have a long fluorescence 
lifetime and an extremely high extinction coefficient. Despite, these advantages there are only two 
compounds, La Jolla Blue® and IRDye 700DX®, belonging to this interesting class commercially 
available. Although these compounds have relatively high fluorescence quatum yields, they can still be 
used as efficient photosensitizers, as demonstrated by, Mitsunaga et al. [58] by conjugation of IRDye 
700DX® to monoclonal antibodies targeting epidermal growth factor receptors. Using these conjugates 
efficient killing of tumor cells was demonstrated in vitro and in vivo when NIR was used as light source. 
Their tendency to aggregate seems to be ideally suited for a relatively new class of fluorescent 
reporters referred to as “smart probes” [241]. This approach has been pioneered by Ralph Weissleder’s 
research group and is based on the selfquenching/dequenching paradigm [242]. In these compounds, 
typically several fluorescent dyes are coupled either directly or via chemically or enzymatically labile 
linker to a polymeric carrier. In their native state these reporters are optically silent due selfquenching 
of the fluorescent dyes. However, as soon as a chemical or enzymatic trigger results in the release of 
the fluorescent dye from its polymeric carrier this selfquenching is abrogated. Today, this methodology 
Molecules 2012, 17              
 
 
127
has been extensively used for the detection of proteolytic activity in vivo. One can deduce from the 
discussions on the photodynamic activity of aggregated Pc above, that these compounds can also be 
used in “smart probes” with a better selfquenching allowing the use of low molecular weight carriers 
with improved pharmacokinetics. Another phenomenon of aggregated Pc, will further favor their use 
in “smart probes”. As the extinction coefficient of the Q-band undergoes significant reduction in the 
aggregated form, these fluorescence reporters not only show reduced fluorescence intensities in the 
non-activated form but also are less sensitive to excitation. Furthermore, due to their lipophilicity, once 
cleaved, Pc dyes will stay longer at the activation site due to reduced clearance. Currently, we are 
evaluating this approach for simultaneously treating and monitoring diseases with Pc-based polymeric 
photosensitizer prodrugs [243-245]. 
4. Conclusions 
Throughout this review, it has been shown that phthalocyanines are promising photosensitizers for 
photodynamic therapy applications. Some of them are even currently used in PDT (e.g., Photosens®) 
or tested in clinical trials (e.g., Pc 4). At a chemical level, it is concluded that Pcs’ mainly amphiphilic 
character leads to a higher efficiency in vivo. In addition, hampering their stacking via axial ligation 
and including positive charge(s) seems to influence their photocytotoxicity, by increasing their cellular 
uptake and internalization. It is also of major importance to consider their subsequent cellular 
(re)localization in order to understand and evaluate their photodynamic activity. Hence, by only 
considering their chemistry, phthalocyanines exhibit this flexibility, enabling further screening and 
investigations, which rises hope for cancer treatment. Perspectives such as chemical coupling of two 
photosensitizers as well as screening of new phthalocyanines are currently examined and could be 
interesting prospects for PDT cancer treatment [246-249]. 
From a pharmaceutical point of view, suitable and optimal formulations of Pcs can increase 
dramatically the therapeutic efficacy. Suitable drug delivery systems can act as a solubilizing matrix 
for the PS as well as a shield and protection from degradation. 
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